MDManuel B. Datiles

Manuel B. Datiles

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manuel B. Datiles has a total of 309 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Congenital and Hereditary Cataracts: Epidemiology and Genetics

    by Nadav Shoshany, Fielding Hejtmancik, Alan Shiels, Manuel B. Datiles


  • Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients

    by Ana Zelic Kerep, Jacob Broome, Filip Pirsl, Lauren M. Curtis, Seth M. Steinberg, Sandra A. Mitchell, Edward W. Cowen, Dominique C. Pichard, Galen O. Joe, Leora E. Comis, et al.

    In 2005, the National Institutes of Health (NIH) chronic graft-versus-host disease (cGVHD) consensus project provided diagnosis and staging criteria, based mostly on clinical experience and expert opinion. These criteria were revised in 2014, aiming to provide enhanced specificity and clarity. However, the impact of 2014 changes to the original NIH cGVHD severity scoring criteria has not been reported. In this study, 284 patients, prospectively enrolled on the National Cancer Institute's cross-sectional cGVHD natural history study, were scored using the 2005 NIH cGVHD criteria and then rescored according to the 2014 modifications. In comparing the two criteria, 2014 cGVHD global severity scoring resulted in a tendency toward being categorized as milder scores (75 vs. 72% of severe score per 2014, p = 0.0009), with a statistically significant shift in NIH liver and lung scores toward milder categories (p < 0.0001). 2005 and 2014 NIH global severity scores showed a significant association with reduced grip strength (p < 0.0001), reduced joint range of motion (p = 0.0003), and the subspecialist evaluation score (p < 0.0001). Poor survival prediction of the severe NIH lung score is also retained in the new criteria (p = 0.0012). These findings support the use of 2014 cGVHD scoring criteria in continuous efforts to develop better classification systems.


  • Open Access

    Congenital Cataracts: Classification and Association With Anterior Segment Abnormalities

    by Manuel B. Datiles, J. Fielding Hejtmancik

    The American Academy of Ophthalmology and Otolaryngology (later the American Academy of Ophthalmology/AAO) published a manual, titled ''Cataract Types,'' by Frederick C. Cordes, MD, as part of its Continuing Education Program in 1961, 1 which served as a practical guide for the classification of congenital cataracts for generations of AAO members. It contained a complex and confusing scheme to describe myriad types of congenital cataract that was difficult to apply clinically. Jules Francois published in 1963 a monumental textbook on congenital cataracts, 2 which contained similar descriptions of myriad types of congenital cataracts. More recently, Amaya et al., 3 Reddy et al., 4 and Hejtmancik 5 published excellent reviews on correlating the lens phenotype with known molecular genetic abnormalities of congenital and childhood cataracts. The lens phenotypes were quite varied and were categorized based on a combination of anatomic location, etiology, and descriptions of the shapes of the lenses, which were still complex and cumbersome to use in the clinic. In this issue of IOVS, Lin et al. 6 propose a simplified clinical classification based on anatomic location with correlation to coexisting anterior segment abnormalities discovered using Scheimpflug imaging, performed under chloral hydrate sedation, of 598 eyes of 428 patients. These findings suggest that genetic and other factors that caused the cataracts may also affect the cornea, iris, and other anterior segment tissues. Hence a more thorough eye examination using newly available technology should be conducted to allow correlation of genetic abnormalities, not only to the lens but also to abnormalities of the cornea and iris. This is a pilot use of this classification system, and further development of a simple but comprehensive clinical classification system for congenital cataracts that is easy to use in practice should be undertaken. Perhaps it would be useful to have a Consensus Conference on this issue at some point.


  • Open Access

    Complicated spastic paraplegia in patients with AP5Z1 mutations (SPG48)

    by Jennifer Hirst, Marianna Madeo, Katrien Smets, James R. Edgar, Ludger Schols, Jun Li, Anna Yarrow, Tine Deconinck, Jonathan Baets, Elisabeth Van Aken, et al.

    Objective: Biallelic mutations in the AP5Z1 gene encoding the AP-5 ζ subunit have been described in a small number of patients with hereditary spastic paraplegia (HSP) (SPG48); we sought to define genotype–phenotype correlations in patients with homozygous or compound heterozygous sequence variants predicted to be deleterious. Methods: We performed clinical, radiologic, and pathologic studies in 6 patients with biallelic mutations in AP5Z1. Results: In 4 of the 6 patients, there was complete loss of AP-5 ζ protein. Clinical features encompassed not only prominent spastic paraparesis but also sensory and motor neuropathy, ataxia, dystonia, myoclonus, and parkinsonism. Skin fibroblasts from affected patients tested positive for periodic acid Schiff and autofluorescent storage material, while electron microscopic analysis demonstrated lamellar storage material consistent with abnormal storage of lysosomal material. Conclusions: Our findings expand the spectrum of AP5Z1-associated neurodegenerative disorders and point to clinical and pathophysiologic overlap between autosomal recessive forms of HSP and lysosomal storage disorders.


  • Reply

    by Manuel B. Datiles, Frederick Ferris, Rafat R. Ansari, J. Samuel Zigler

  • Open Access

    Erratum to “Salivary Gland Involvement in Chronic Graft-versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation” [Biol Blood Marrow Transplant 16:1362-1369]

    by Matin M. Imanguli, Jane C. Atkinson, Sandra A. Mitchell, Daniele N. Avila, Rachel J. Bishop, Edward W. Cowen, Manuel B. Datiles, Frances T. Hakim, David E. Kleiner, Michael C. Krumlauf, et al.


  • Longitudinal Study of Age-Related Cataract Using Dynamic Light Scattering

    by Manuel B. Datiles, Rafat R. Ansari, Junko Yoshida, Holly Brown, Andrea I. Zambrano, Jing Tian, Susan Vitale, J. Samuel Zigler, Frederick L. Ferris, Sheila K. West, et al.


  • Open Access

    Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice

    by L. M. Curtis, M. B. Datiles, S. M. Steinberg, S. A. Mitchell, R. J. Bishop, E. W. Cowen, J. Mays, J. M. McCarty, Z. Kuzmina, F. Pirsl, et al.

    Ocular chronic graft-versus-host disease is one of the most bothersome common complications after allogeneic hematopoietic stem cell transplantation. The National Institutes of Health Chronic Graft-versus-Host Disease Consensus Project provided expert recommendations for diagnosis and organ severity scoring, however, ocular chronic graft-versus-host disease can be diagnosed only after examination by an ophthalmologist. There are no currently accepted definitions of ocular chronic graft-versus-host disease activity. The goal of this study was to identify predictive models of diagnosis and activity for use in clinical transplant practice. 210 patients with moderate or severe chronic graft-versus-host disease were enrolled in a prospective, cross-sectional, observational study ([NCT00092235][1]). Experienced ophthalmologists determined presence of ocular chronic graft-versus-host disease diagnosis and activity. Measures gathered by the transplant clinician included Schirmer's tear test and National Institutes of Health 0-3 Eye Score. Patient-reported outcome measures were the ocular subscale of the Lee Chronic Graft-versus-Host Disease Symptom Scale and Chief Eye Symptom Intensity Score. 157 (75%) patients were diagnosed with ocular chronic graft-versus-host disease; (133/157; 85%) had active disease. In a multivariable model, the National Institutes of Health Eye Score (p<0.0001) and Schirmer's tear test (p<0.0001) were independent predictors of ocular chronic graft-versus-host disease (sensitivity 93.0%, specificity 92.2%). The Lee ocular subscale was the strongest predictor of active ocular chronic graft-versus-host disease (p<0.0001) (sensitivity 68.5%, specificity 82.6%). Ophthalmology specialist measures that were most strongly predictive of diagnosis in a multivariate model were Oxford grand total staining (p<0.0001) and meibomian score (p=0.027). These results support the use of selected transplant clinician- and patient-reported outcome measures for ocular chronic graft-versus-host disease screening when providing care to allogeneic hematopoietic stem cell transplantation survivors with moderate to severe chronic graft-versus-host disease. Prospective studies are needed to determine if the Lee ocular subscale demonstrates adequate responsiveness as a disease activity outcome measure. ([NCT00092235][1]) [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00092235&atom=%2Fhaematol%2Fearly%2F2015%2F06%2F16%2Fhaematol.2015.124131.atom


  • Oral Disease Profiles in Chronic Graft versus Host Disease

    by C.W. Bassim, H. Fassil, J.W. Mays, D. Edwards, K. Baird, S.M. Steinberg, E.W. Cowen, H. Naik, M. Datiles, P. Stratton, et al.

    At least half of patients with chronic graft-versus-host-disease (cGVHD), the leading cause of morbidity and non-relapse mortality after allogeneic stem cell transplantation, have oral manifestations: mucosal lesions, salivary dysfunction, and limited mouth-opening. cGVHD may manifest in a single organ or affect multiple organ systems, including the mouth, eyes, and the skin. The interrelationship of the 3 oral manifestations of cGVHD with each other and with the specific manifestations of extraoral cGVHD has not been studied. In this analysis, we explored, in a large group of patients with cGVHD, the potential associations between: (1) oral mucosal disease and erythematous skin disease, (2) salivary gland dysfunction and lacrimal gland dysfunction, and (3) limited mouth-opening and sclerotic skin cGVHD. Study participants, enrolled in a cGVHD Natural History Protocol (NCT00331968, n = 212), underwent an oral examination evaluating: (1) mucosal cGVHD [NIH Oral Mucosal Score (OMS)], (2) salivary dysfunction (saliva flow and xerostomia), and (3) maximum mouth-opening measurement. Parameters for dysfunction (OMS > 2, saliva flow ≤ 1 mL/5 min, mouth-opening ≤ 35 mm) were analyzed for association with skin cGVHD involvement (erythema and sclerosis, skin symptoms), lacrimal dysfunction (Schirmer’s tear test, xerophthalmia), Lee cGVHD Symptom Scores, and NIH organ scores. Oral mucosal disease (31% prevalence) was associated with skin erythema (P < 0.001); salivary dysfunction (11% prevalence) was associated with lacrimal dysfunction (P = 0.010) and xerostomia with xerophthalmia (r = 0.32, P = 0.001); and limited mouth-opening (17% prevalence) was associated with skin sclerosis (P = 0.008) and skin symptoms (P = 0.001). There was no association found among these 3 oral cGVHD manifestations. This analysis supports the understanding of oral cGVHD as 3 distinct diseases: mucosal lesions, salivary gland dysfunction, and mouth sclerosis. Clear classification of oral cGVHD as 3 separate manifestations will improve clinical diagnosis, observational research data collection, and the definitions of outcome measures in clinical trials.


  • Top Cited Papers
    Open Access

    National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

    by Madan H. Jagasia, Hildegard T. Greinix, Mukta Arora, Kirsten M. Williams, Daniel Wolff, Edward W. Cowen, Jeanne Palmer, Daniel Weisdorf, Nathaniel S. Treister, Guang-Shing Cheng, et al.